Montag A & Associates Inc Crispr Therapeutics Ag Transaction History

Montag A & Associates Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$41.0 - $56.12 $4,100 - $5,612	-100 Reduced 57.14%	75 $3,000
Q4 2022 Feb 02, 2023	SELL	$39.19 - $65.67 $3,919 - $6,567	-100 Reduced 36.36%	175 $7,000
Q3 2022 Nov 09, 2022	SELL	$61.1 - $83.78 $44,786 - $61,410	-733 Reduced 72.72%	275 $18,000
Q2 2022 Aug 10, 2022	SELL	$43.23 - $73.83 $37,177 - $63,493	-860 Reduced 46.04%	1,008 $61,000
Q1 2022 May 02, 2022	SELL	$53.19 - $79.24 $23,190 - $34,548	-436 Reduced 18.92%	1,868 $117,000
Q4 2021 Feb 09, 2022	SELL	$70.09 - $111.29 $138,007 - $219,130	-1,969 Reduced 46.08%	2,304 $174,000
Q3 2021 Nov 08, 2021	BUY	$110.2 - $156.64 $8,705 - $12,374	79 Added 1.88%	4,273 $478,000
Q2 2021 Aug 03, 2021	BUY	$100.84 - $161.89 $10,285 - $16,512	102 Added 2.49%	4,194 $679,000
Q1 2021 May 14, 2021	SELL	$110.72 - $210.04 $23,251 - $44,108	-210 Reduced 4.88%	4,092 $499,000
Q4 2020 Feb 12, 2021	BUY	$79.67 - $173.23 $21,670 - $47,118	272 Added 6.75%	4,302 $659,000
Q3 2020 Nov 12, 2020	BUY	$78.5 - $100.64 $316,355 - $405,579	4,030 New	4,030 $337,000

491

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.74B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Montag A & Associates Inc, based on Form 13F filings with the SEC.

Stay updated on Montag A & Associates Inc with notifications on news.